HALISTER: Amgen’s Repatha Reduced Risk of CV Events in Outcomes Study

Amgen’s Repatha Reduced Risk of CV Events in Outcomes Study

(Bloomberg) -- Amgen said Repatha significantly reduced the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease in the “Fourier” Phase 3 outcomes trial.
  • Repatha met primary composite endpoint and key secondary composite endpoint
  • “Ebbinghaus” trial conducted in Fourier patients also met primary endpoint of showing Repatha was non- inferior to placebo for the effect on cognitive function
  • AMGN will present the data March 17-18 at the American College of Cardiology meeting
  • NOTE: AMGN reports 4Q results post-market; call at 5pm
  • NOTE: Feb. 1, Amgen Raised at BofAML on Biosimilar Win, Repatha Data Potential
To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net To contact the editors responsible for this story: Arie Shapira at ashapira3@bloomberg.net Catherine Larkin
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
AMGN US (Amgen Inc)

To de-activate this alert, click here

UUID: 7947283